A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Casopitant (Primary) ; Ondansetron
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 16 Oct 2006 Status change
- 20 Oct 2005 New trial record.